Press Releases

A comprehensive library of Ipsen media releases for investors and members of the press.

Key highlights

Explore more press releases

Filter

Topics

Period

Filter by

recent search

Reset

Showing: 1 – 05 of 30 Press Releases

Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma
Press Release Icon  –  09 November 2022

09 November 2022

Download Press Release
Onivyde® regimen demonstrated statistically significant improvement in overall survival in previously untreated metastatic pancreatic ductal adenocarcinoma

PARIS, FRANCE, 9 November 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) announced the Phase III NAPOLI 3 trial of Onivyde® (irinotecan liposome injection) plus 5 fluorouracil/leucovorin and oxaliplatin (NALIRIFOX regimen) met its primary endpoint d


Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance
Press Release Icon  –  27 October 2022

27 October 2022

Download Press Release
Ipsen delivers strong sales growth in the first nine months of 2022 and confirms its full-year guidance

Paris (France), 27 October 2022


Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting
Press Release Icon  –  25 October 2022

25 October 2022

Download Press Release
Ipsen statement on updated timeline for palovarotene FDA Advisory Committee meeting

PARIS, FRANCE, 25 October 2022 – Ipsen (Euronext: IPN; ADR: IPSEY) reports that the U.S. Food and Drug Administration (FDA) has today announced its decision to postpone the planned Endocrinologic and Metabolic Drugs Advisory Committee meeting for in


Ipsen’s global Natural History Study of Fibrodysplasia Ossificans Progressiva shows debilitating impact of the disease over an individual’s lifetime
Press Release Icon  –  28 September 2022

28 September 2022

Download Press Release
Ipsen’s global Natural History Study of Fibrodysplasia Ossificans Progressiva shows debilitating impact of the disease over an individual’s lifetime

First prospective study to assess the association of fibrodysplasia ossificans progressive (FOP) flare-ups and extra-skeletal bone growth (heterotopic ossification or HO) with functional impairment


First international Fibrodysplasia Ossificans Progressiva (FOP) Burden of Illness Survey reveals extent of social, economic, and quality of life impact of disease
Press Release Icon  –  05 September 2022

05 September 2022

Download Press Release
First international Fibrodysplasia Ossificans Progressiva (FOP) Burden of Illness Survey reveals extent of social, economic, and quality of life impact of disease

Findings published in the Expert Review of Pharmacoeconomics & Outcomes Research demonstrate progressive loss of joint mobility and function is associated with a considerable, negative impact on quality of life for those living with FOPSurvey co-create


1 2 3 4 5 6

Your dedicated contacts

Related links